Profile data is unavailable for this security.

About the company

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

  • Revenue in USD (TTM)49.57bn
  • Net income in USD7.21bn
  • Incorporated1996
  • Employees109.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:VTX since
Shire US Inc-Xiidra AssetsDeal completed08 May 201908 May 2019Deal completed6.93%5.30bn
IFM Tre IncDeal completed01 Apr 201901 Apr 2019Deal completed-7.39%1.58bn
CELLforCURE SASUDeal completed20 Dec 201820 Dec 2018Deal completed4.85%--
Data delayed at least 15 minutes, as of Nov 15 2019 16:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Chugai Pharmaceutical Co Ltd6.09bn1.28bn47.24bn7.43k36.056.18--7.76254.58254.581,208.131,485.300.69121.623.5889,100,910.0014.578.4017.359.9359.2552.3221.0813.072.80--0.0050.538.536.4827.2012.6939.019.86
Takeda Pharmaceutical Co Ltd26.45bn143.84m64.59bn49.58k138.811.4312.722.4432.1032.102,130.243,123.560.33541.864.6458,025,380.000.18431.360.21551.7765.2269.830.54943.830.93820.47140.5078226.3318.454.39-41.610.458611.300.00
Bayer AG48.47bn-1.65bn72.59bn104.71k--1.4318.341.50-1.53-1.3044.6949.290.33571.733.74374,852.60-1.144.12-1.395.2857.4258.83-3.398.160.88264.110.486969.6713.05-0.286-47.83-11.873.756.26
Novartis AG (ADR)49.57bn7.21bn226.95bn109.00k29.033.8817.704.583.105.0721.3023.190.38292.216.04396,065.905.576.817.138.4170.9066.5514.5517.420.728357.900.364174.616.050.170265.026.53-0.13663.89
Roche Holding Ltd.59.81bn11.90bn257.98bn94.44k21.699.0315.844.3113.6513.6968.6832.780.74772.455.33626,882.1015.4312.8223.0319.0571.2171.1520.6418.761.1032.820.386975.826.653.9719.61-1.2818.772.21
Data as of Nov 15 2019. Currency figures normalised to Novartis AG's reporting currency: US Dollar USD

Institutional shareholders

4.39%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 30 Sep 201926.77m1.06%
PRIMECAP Management Co.as of 30 Sep 201925.54m1.01%
Franklin Mutual Advisers LLCas of 30 Sep 201912.23m0.48%
Fisher Asset Management LLCas of 30 Sep 20198.31m0.33%
UBS Financial Services, Inc.as of 30 Sep 20197.58m0.30%
Loomis, Sayles & Co. LPas of 30 Sep 20197.10m0.28%
Fidelity Management & Research Co.as of 30 Sep 20196.39m0.25%
Mawer Investment Management Ltd.as of 30 Sep 20195.99m0.24%
Managed Account Advisors LLCas of 30 Sep 20195.81m0.23%
Renaissance Technologies LLCas of 30 Sep 20195.21m0.21%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.